No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
22 Feb 2024
22 Feb 2024
Historique:
received:
13
06
2023
accepted:
05
02
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
22
2
2024
Statut:
epublish
Résumé
Type I interferons act as gatekeepers against viral infection, and autoantibodies that neutralize these signaling molecules have been associated with COVID-19 severity and adverse reactions to the live-attenuated yellow fever vaccine. On this background, we sought to examine whether autoantibodies against type I interferons were associated with adverse events following COVID-19 vaccination. Our nationwide analysis suggests that type I interferon autoantibodies were not associated with adverse events after mRNA or viral-vector COVID-19 vaccines.
Identifiants
pubmed: 38388530
doi: 10.1038/s41541-024-00829-9
pii: 10.1038/s41541-024-00829-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42Subventions
Organisme : Knut och Alice Wallenbergs Stiftelse (Knut and Alice Wallenberg Foundation)
ID : KAW 2021.0010_VC-2020-0040
Organisme : Vetenskapsrådet (Swedish Research Council)
ID : 2021-05450
Organisme : Vetenskapsrådet (Swedish Research Council)
ID : 2021-03118
Informations de copyright
© 2024. The Author(s).
Références
Chatterjee, A. & Chakravarty, A. Neurological complications following COVID-19 vaccination. Curr. Neurol. Neurosci. Rep. 23, 1–14 (2023).
doi: 10.1007/s11910-022-01247-x
pubmed: 36445631
Rabail, R. et al. The side effects and adverse clinical cases reported after COVID-19 immunization. Vaccines 10, https://doi.org/10.3390/vaccines10040488 (2022).
Lamprinou, M., Sachinidis, A., Stamoula, E., Vavilis, T. & Papazisis, G. COVID-19 vaccines adverse events: Potential molecular mechanisms. Immunologic Research, https://doi.org/10.1007/s12026-023-09357-5 (2023).
Schultz, N. H. et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N. Engl. J. Med. 384, 2124–2130 (2021).
doi: 10.1056/NEJMoa2104882
pubmed: 33835768
Lee, J. S. & Shin, E.-C. The type I interferon response in COVID-19: Implications for treatment. Nat. Rev. Immunol. 20, 585–586 (2020).
doi: 10.1038/s41577-020-00429-3
pubmed: 32788708
pmcid: 8824445
Zhang, Q. et al. Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J. Exp. Med. 219, https://doi.org/10.1084/jem.20220514 (2022).
Gervais, A. et al. Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients. J. Exp. Med. 220, https://doi.org/10.1084/jem.20230661 (2023).
Wang, X. et al. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis. Int. J. Infect. Dis. 130, 147–152 (2023).
doi: 10.1016/j.ijid.2023.03.011
pubmed: 36907547
pmcid: 10005838
Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabl4340 (2021).
doi: 10.1126/sciimmunol.abl4340
pubmed: 34413139
pmcid: 8521484
Bastard, P. et al. Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, https://doi.org/10.1084/jem.20202486 (2021).
Pomara, C. et al. COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis. Diagnostics (Basel) 11, https://doi.org/10.3390/diagnostics11060955 (2021).
Meager, A. et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med. 3, e289 (2006).
doi: 10.1371/journal.pmed.0030289
pubmed: 16784312
pmcid: 1475653
Lemarquis, A. et al. Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis. J. Allergy Clin. Immunol. 148, 96–98 (2021).
doi: 10.1016/j.jaci.2021.03.034
pubmed: 33892926
pmcid: 8051851
Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020).
doi: 10.1126/science.abd4585
pubmed: 32972996
pmcid: 7857397
Rodrigues, C. M. C. & Plotkin, S. A. Impact of vaccines; health, economic and social perspectives. Front. Microbiol. 11, 1526 (2020).
doi: 10.3389/fmicb.2020.01526
pubmed: 32760367
pmcid: 7371956
Thurner, L. et al. IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination. N. Engl. J. Med. 387, 1524–1527 (2022).
doi: 10.1056/NEJMc2205667
pubmed: 36130012
McKean, N. & Chircop, C. Guillain-Barré syndrome after COVID-19 vaccination. BMJ Case Rep. 14, https://doi.org/10.1136/bcr-2021-244125 (2021).
Gao, J. J. et al. Acute transverse myelitis following COVID-19 vaccination. Vaccines 9, https://doi.org/10.3390/vaccines9091008 (2021).
Kounis, N. G. et al. Allergic reactions to current available COVID-19 vaccinations: Pathophysiology, causality, and therapeutic considerations. Vaccines 9, https://doi.org/10.3390/vaccines9030221 (2021).
Sokal, A. et al. Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination. J. Exp. Med. 220, https://doi.org/10.1084/jem.20220258 (2023).
Scully, M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N. Engl. J. Med. 384, 2202–2211 (2021).
doi: 10.1056/NEJMoa2105385
pubmed: 33861525
Muir, K.-L., Kallam, A., Koepsell, S. A. & Gundabolu, K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N. Engl. J. Med. 384, 1964–1965 (2021).
doi: 10.1056/NEJMc2105869
pubmed: 33852795
Arrestier, R. et al. Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study. Ann. Intensive Care 12, 121 (2022).
doi: 10.1186/s13613-022-01095-5
pubmed: 36586050
pmcid: 9803887
R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2023).